Evoke Pharma Inc expected to post a loss of 30 cents a share - Earnings Preview

Evoke Pharma

08/08/2025 12:26

Evoke Pharma Inc EVOK.OQ EVOK.O is expected to  show a rise in quarterly revenue when it reports  results on August 11 (estimated) for the period ending June 30 2025

The Solana Beach California-based  company is expected to report a 48.8% increase in revenue to $3.796 million from $2.55 million a year ago, according to the estimate from one analyst, based on LSEG data.

​LSEG's mean analyst estimate for Evoke Pharma Inc is for a loss of 30 cents per share.

The one available analyst rating on the shares is "buy".

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Evoke Pharma Inc is $18.00, about 70.4% above its last closing price of $5.33

This summary was machine generated August 8 at 11:26 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)